Molecular aspects of myeloproliferative neoplasms

International Journal of Hematology

Volumn 91, Issue 2, 2010, Pages 165-173

  Delhommeau, François ^a,b   Jeziorowska, Dorota ^b,c   Marzac, Christophe ^b   Casadevall, Nicole ^a,b  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

ASXL1; CBL; JAK2; MPL; Myeloproliferative neoplasms; TET2

Indexed keywords

CBL PROTEIN; DIOXYGENASE; ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; POLYCOMB GROUP PROTEIN; PROTEIN ASXL1; TEN ELEVEN TRANSLOCATION 1 PROTEIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULAR GENETICS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; POLYCYTHEMIA VERA; PROTEIN FUNCTION; REVIEW; RISK FACTOR; THROMBOCYTHEMIA;

EID: 77950917237     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-010-0530-z     Document Type: Review

References (65)

1. C James V Ugo JP Le Couedic J Staerk F Delhommeau C Lacout, et al. 2005 A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 1144 1148 10.1038/nature03546 1:CAS:528: DC%2BD2MXjsF2ltbk%3D 15793561 (Pubitemid 40663494)
2. EJ Baxter LM Scott PJ Campbell C East N Fourouclas S Swanton, et al. 2005 Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054 1061 1:CAS:528:DC%2BD2MXisFGrs7g%3D 15781101 (Pubitemid 40386783)
3. R Kralovics F Passamonti AS Buser SS Teo R Tiedt JR Passweg, et al. 2005 A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med 352 1779 1790 10.1056/NEJMoa051113 1:CAS:528:DC%2BD2MXjsFyhsLw%3D 15858187 (Pubitemid 40570926)
4. RL Levine M Wadleigh J Cools BL Ebert G Wernig BJ Huntly, et al. 2005 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 387 397 10.1016/j.ccr.2005.03.023 1:CAS:528:DC%2BD2MXjvFSku7o%3D 15837627 (Pubitemid 40544655)
5. R Zhao S Xing Z Li X Fu Q Li SB Krantz, et al. 2005 Identification of an acquired JAK2 mutation in polycythemia vera J Biol Chem 280 22788 22792 10.1074/jbc.C500138200 1:CAS:528:DC%2BD2MXltVyhtro%3D 15863514 (Pubitemid 40853184)
6. N Casadevall W Vainchenker C Lacombe G Vinci J Chapman J Breton-Gorius, et al. 1982 Erythroid progenitors in polycythemia vera: demonstration of their hypersensitivity to erythropoietin using serum free cultures Blood 59 447 451 1:STN:280:DyaL387hsVWitg%3D%3D 7055650 (Pubitemid 12172040)
7. JJ Michiels H De Raeve K Hebeda KH Lam Z Berneman W Schroyens, et al. 2007 WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders Leuk Res 31 1031 1038 10.1016/j.leukres.2007.01.021 1:CAS:528:DC%2BD2sXmtlamsbw%3D 17367853 (Pubitemid 46881088)
8. J Kota N Caceres SN Constantinescu 2008 Aberrant signal transduction pathways in myeloproliferative neoplasms Leukemia 22 1828 1840 10.1038/leu.2008.236 1:CAS:528:DC%2BD1cXht1Cms7zF 18769448
9. LJ Huang SN Constantinescu HF Lodish 2001 The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor Mol Cell 8 1327 1338 10.1016/S1097-2765(01)00401-4 1:CAS:528:DC%2BD38XivFGmtg%3D%3D 11779507 (Pubitemid 34085003)
10. Y Royer J Staerk M Costuleanu PJ Courtoy SN Constantinescu 2005 Janus kinases affect thrombopoietin receptor cell surface localization and stability J Biol Chem 280 27251 27261 10.1074/jbc.M501376200 1:CAS:528:DC%2BD2MXmt1Ggtb0%3D 15899890 (Pubitemid 41040765)
11. AR Moliterno WD Hankins JL Spivak 1998 Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera N Engl J Med 338 572 580 10.1056/NEJM199802263380903 1:STN:280:DyaK1c7ivFWmsg%3D%3D 9475764 (Pubitemid 28114645)
12. J Staerk A Kallin JB Demoulin W Vainchenker SN Constantinescu 2005 JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor J Biol Chem 280 41893 41899 10.1074/jbc.C500358200 1:CAS:528:DC%2BD2MXhtlajsrjL 16239216 (Pubitemid 43023158)
13. X Lu R Levine W Tong G Wernig Y Pikman S Zarnegar, et al. 2005 Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation Proc Natl Acad Sci USA 102 18962 18967 10.1073/pnas.0509714102 1:CAS:528:DC%2BD28XivV2jtQ%3D%3D 16365288 (Pubitemid 43049549)
14. S Dupont A Masse C James I Teyssandier Y Lecluse F Larbret, et al. 2007 The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera Blood 110 1013 1021 10.1182/blood-2006-10-054940 1:CAS:528:DC%2BD2sXos1Cqtrw%3D 17389763 (Pubitemid 47267441)
15. LM Scott MA Scott PJ Campbell AR Green 2006 Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia Blood 108 2435 2437 10.1182/blood-2006-04-018259 1:CAS:528:DC%2BD28XhtVCgurzL 16772604 (Pubitemid 44497530)
16. F Delhommeau DF Pisani C James N Casadevall S Constantinescu W Vainchenker 2006 Oncogenic mechanisms in myeloproliferative disorders Cell Mol Life Sci 63 2939 2953 10.1007/s00018-006-6272-7 1:CAS:528:DC%2BD2sXht1egtbs%3D 17131059 (Pubitemid 46072300)
17. LM Scott W Tong RL Levine MA Scott PA Beer MR Stratton, et al. 2007 JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis N Engl J Med 356 459 468 10.1056/NEJMoa065202 1:CAS:528:DC%2BD2sXht1ersrc%3D 17267906 (Pubitemid 46193073)
18. CM Butcher U Hahn LB To J Gecz EJ Wilkins HS Scott, et al. 2008 Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients Leukemia 22 870 873 10.1038/sj.leu.2404971 1:CAS:528:DC%2BD1cXks12rt74%3D 17914411 (Pubitemid 351552644)
19. AD Pardanani RL Levine T Lasho Y Pikman RA Mesa M Wadleigh, et al. 2006 MPl515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Blood 108 3472 3476 10.1182/blood-2006-04-018879 1:CAS:528:DC%2BD28Xht1ahsLzI 16868251
20. Y Pikman BH Lee T Mercher E McDowell BL Ebert M Gozo, et al. 2006 MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia PLoS Med 3 e270 10.1371/journal.pmed.0030270 16834459 (Pubitemid 44125998)
21. R Chaligne C James C Tonetti R Besancenot JP Le Couedic F Fava, et al. 2007 Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis Blood 110 3735 3743 10.1182/blood-2007-05-089003 1:CAS:528:DC%2BD2sXhtlarurvF 17709604 (Pubitemid 350159644)
22. PA Beer PJ Campbell LM Scott AJ Bench WN Erber D Bareford, et al. 2008 MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort Blood 112 141 149 10.1182/blood-2008-01-131664 1:CAS:528:DC%2BD1cXotlylsrc%3D 18451306
23. J Staerk C Lacout T Sato SO Smith W Vainchenker SN Constantinescu 2006 An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor Blood 107 1864 1871 10.1182/blood-2005-06-2600 1:CAS:528:DC%2BD28XitFChsbg%3D 16249382 (Pubitemid 43289364)
24. C James F Mazurier S Dupont R Chaligne I Lamrissi-Garcia M Tulliez, et al. 2008 The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity Blood 112 2429 2438 10.1182/blood-2008-02-137877 1:CAS:528:DC%2BD1cXhtFCru77E 18612101
25. I Dikic I Szymkiewicz P Soubeyran 2003 Cbl signaling networks in the regulation of cell function Cell Mol Life Sci 60 1805 1827 10.1007/s00018-003- 3029-4 1:CAS:528:DC%2BD3sXotF2jt7s%3D 14523545 (Pubitemid 37222580)
26. FH Grand CE Hidalgo-Curtis T Ernst K Zoi C Zoi C McGuire, et al. 2009 Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms Blood 113 6182 6192 10.1182/blood-2008-12-194548 1:CAS:528:DC%2BD1MXnslSmu7Y%3D 19387008
27. M Sanada T Suzuki LY Shih M Otsu M Kato S Yamazaki, et al. 2009 Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms Nature 460 904 908 10.1038/nature08240 1:CAS:528:DC%2BD1MXoslentrg%3D 19620960
28. O Abdel-Wahab T Manshouri J Patel K Harris J Yao C Hedvat, et al. 2010 Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias Cancer Res 70 447 452 10.1158/0008-5472.CAN-09-3783 1:CAS:528:DC%2BC3cXltlWksQ%3D%3D 20068184
29. H Makishima H Cazzolli H Szpurka A Dunbar R Tiu J Huh, et al. 2009 Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies J Clin Oncol 27 6109 6116 10.1200/JCO.2009.23.7503 1:CAS:528:DC%2BC3cXht1agsLk%3D 19901108
30. M Shannon KandLoh 2009 Cancer: more than kin and less than kind Nature 460 804 807 10.1038/460804a
31. F Delhommeau S Dupont C Tonetti A Masse I Godin JP Le Couedic, et al. 2007 Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis Blood 109 71 77 10.1182/blood-2006-03-007146 1:CAS:528:DC%2BD2sXivVyrtL0%3D 16954506 (Pubitemid 46053046)
32. AD Wood E Chen IJ Donaldson S Hattangadi KA Burke MA Dawson, et al. 2009 ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling Blood 114 1820 1830 10.1182/blood-2009-02-206573 1:CAS:528:DC%2BD1MXhtFWgsbbF 19571317
33. S Xing TH Wanting W Zhao J Ma S Wang X Xu, et al. 2008 Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice Blood 111 5109 5117 10.1182/blood-2007-05-091579 1:CAS:528:DC%2BD1cXmtlahs74%3D 18334677
34. C Lacout DF Pisani M Tulliez FM Gachelin W Vainchenker JL Villeval 2006 JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis Blood 108 1652 1660 10.1182/blood-2006-02-002030 1:CAS:528:DC%2BD28Xpt1Sltbg%3D 16670266 (Pubitemid 44316134)
35. G Wernig T Mercher R Okabe RL Levine BH Lee DG Gilliland 2006 Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model Blood 107 4274 4281 10.1182/blood-2005-12-4824 1:CAS:528:DC%2BD28Xlt1Cgs7k%3D 16478879 (Pubitemid 43801351)
36. R Tiedt H Hao-Shen MA Sobas R Looser S Dirnhofer J Schwaller, et al. 2008 Ratio of mutant JAK2-V617F to wild-type jak2 determines the MPD phenotypes in transgenic mice Blood 111 3931 3940 10.1182/blood-2007-08-107748 1:CAS:528:DC%2BD1cXkvFeju7k%3D 18160670
37. RH Nussenzveig SI Swierczek J Jelinek A Gaikwad E Liu S Verstovsek, et al. 2007 Polycythemia vera is not initiated by JAK2V617F mutation Exp Hematol 35 32 38 10.1016/j.exphem.2006.11.012 1:CAS:528:DC%2BD2sXhsFKnsQ%3D%3D 17198871 (Pubitemid 46014382)
38. R Kralovics SS Teo S Li A Theocharides AS Buser A Tichelli, et al. 2006 Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders Blood 108 1377 1380 10.1182/blood-2005-11-009605 1:CAS:528:DC%2BD28Xot1ymu70%3D 16675710 (Pubitemid 44232040)
39. RL Levine C Belisle M Wadleigh D Zahrieh S Lee P Chagnon, et al. 2006 X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis Blood 107 4139 4141 10.1182/blood-2005-09-3900 1:CAS:528:DC%2BD28XkvFWgs7s%3D 16434490 (Pubitemid 43726824)
40. A Theocharides M Boissinot F Girodon R Garand SS Teo E Lippert, et al. 2007 Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation Blood 110 375 379 10.1182/blood-2006-12-062125 1:CAS:528:DC%2BD2sXnsVait74%3D 17363731 (Pubitemid 47026857)
41. C Bellanne-Chantelot I Chaumarel M Labopin F Bellanger V Barbu C De Toma, et al. 2006 Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders Blood 108 346 352 10.1182/blood-2005-12-4852 1:CAS:528:DC%2BD28XmsVOmu7c%3D 16537803 (Pubitemid 43990648)
42. O Landgren LR Goldin SY Kristinsson EA Helgadottir J Samuelsson M Bjorkholm 2008 Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden Blood 112 2199 2204 10.1182/blood-2008- 03-143602 1:CAS:528:DC%2BD1cXhtFCrurvO 18451307
43. AV Jones A Chase RT Silver D Oscier K Zoi YL Wang, et al. 2009 JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms Nat Genet 41 446 449 10.1038/ng.334 1:CAS:528:DC%2BD1MXjtFCis7c%3D 19287382
44. O Kilpivaara S Mukherjee AM Schram M Wadleigh A Mullally BL Ebert, et al. 2009 A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms Nat Genet 41 455 459 10.1038/ng.342 1:CAS:528:DC%2BD1MXjtFCisLw%3D 19287384
45. D Olcaydu A Harutyunyan R Jager T Berg B Gisslinger I Pabinger, et al. 2009 A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms Nat Genet 41 450 454 10.1038/ng.341 1:CAS:528:DC%2BD1MXjtFCisb4%3D 19287385
46. PJ Campbell 2009 Somatic and germline genetics at the JAK2 locus Nat Genet 41 385 386 10.1038/ng0409-385 1:CAS:528:DC%2BD1MXjslartLs%3D 19338077
47. RB Lorsbach J Moore S Mathew SC Raimondi ST Mukatira JR Downing 2003 TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23) Leukemia 17 637 641 10.1038/sj.leu.2402834 1:CAS:528:DC%2BD3sXitFentbY%3D 12646957 (Pubitemid 36395661)
48. M Tahiliani KP Koh Y Shen WA Pastor H Bandukwala Y Brudno, et al. 2009 Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 Science 324 930 935 10.1126/science.1170116 1:CAS:528:DC%2BD1MXlslWnurY%3D 19372391
49. F Delhommeau S Dupont V Della Valle C James S Trannoy A Masse, et al. 2009 Mutation in TET2 in myeloid cancers N Engl J Med 360 2289 2301 10.1056/NEJMoa0810069 19474426
50. Beer PA, Delhommeau F, Lecouedic JP, Dawson MA, Chen E, Bareford D, et al. Two routes to leukemic transformation following a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2009.
51. L Couronne E Lippert J Andrieux O Kosmider I Radford-Weiss D Penther, et al. 2010 Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias Leukemia 24 201 203 10.1038/leu.2009.169 1:STN:280: DC%2BC3c%2FhvFOjug%3D%3D 19710701
52. A Tefferi RL Levine KH Lim O Abdel-Wahab TL Lasho J Patel, et al. 2009 Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates Leukemia 23 900 904 10.1038/leu.2009.37 1:CAS:528:DC%2BD1MXlslCru7g%3D 19262599
53. C Saint-Martin G Leroy F Delhommeau G Panelatti S Dupont C James, et al. 2009 Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms Blood 114 1628 1632 10.1182/blood-2009-01-197525 1:CAS:528:DC%2BD1MXhtVyiurrJ 19564637
54. Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010.
55. F Viguie A Aboura D Bouscary S Ramond A Delmer G Tachdjian, et al. 2005 Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement? Leukemia 19 1411 1415 10.1038/sj.leu.2403818 1:CAS:528: DC%2BD2MXmtlSjsrY%3D 15920487 (Pubitemid 41136336)
56. O Abdel-Wahab A Mullally C Hedvat G Garcia-Manero J Patel M Wadleigh, et al. 2009 Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies Blood 114 144 147 10.1182/blood-2009-03-210039 1:CAS:528:DC%2BD1MXhtVOkurvO 19420352
57. AM Jankowska H Szpurka RV Tiu H Makishima M Afable J Huh, et al. 2009 Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms Blood 113 6403 6410 10.1182/blood-2009-02-205690 1:CAS:528:DC%2BD1MXnvFGns7Y%3D 19372255
58. SM Langemeijer RP Kuiper M Berends R Knops MG Aslanyan M Massop, et al. 2009 Acquired mutations in TET2 are common in myelodysplastic syndromes Nat Genet 41 838 842 10.1038/ng.391 1:CAS:528:DC%2BD1MXms1alu7s%3D 19483684
59. C Acquaviva V Gelsi-Boyer D Birnbaum 2010 Myelodysplastic syndromes: lost between two states? Leukemia 24 1 5 10.1038/leu.2009.157 1:STN:280: DC%2BC3c%2FitFCrtQ%3D%3D 20068572
60. SW Lee YS Cho JM Na UH Park M Kang EJ Kim, et al. 2010 ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1 J Biol Chem 285 18 29 10.1074/jbc.M109.065862 1:CAS:528:DC%2BD1MXhs1SqsbnF 19880879
61. YS Cho EJ Kim UH Park HS Sin SJ Um 2006 Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor J Biol Chem 281 17588 17598 10.1074/jbc.M512616200 1:CAS:528:DC%2BD28XmtFyks7Y%3D 16606617 (Pubitemid 44035558)
62. CL Fisher N Pineault C Brookes CD Helgason H Ohta C Bodner, et al. 2010 Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia Blood 115 38 46 10.1182/blood-2009-07-230698 1:CAS:528:DC%2BC3cXnvVyjsg%3D%3D 19861679
63. V Gelsi-Boyer V Trouplin J Adelaide J Bonansea N Cervera N Carbuccia, et al. 2009 Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia Br J Haematol 145 788 800 10.1111/j.1365-2141.2009.07697.x 1:CAS:528:DC%2BD1MXosVartbw%3D 19388938
64. N Carbuccia A Murati V Trouplin M Brecqueville J Adelaide J Rey, et al. 2009 Mutations of ASXL1 gene in myeloproliferative neoplasms Leukemia 23 2183 2186 10.1038/leu.2009.141 1:CAS:528:DC%2BD1MXhtl2hsrjJ 19609284
65. I Plo M Nakatake L Malivert JP de Villartay S Giraudier JL Villeval, et al. 2008 JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders Blood 112 1402 1412 10.1182/blood-2008-01-134114 1:CAS:528:DC%2BD1cXpvVOktb8%3D 18515659